These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24678081)

  • 1. Postmarketing surveillance of rabeprazole in upper gastrointestinal peptic lesions in Japanese patients with coexisting hepatic disorders.
    Makino I; Nakamura K; Sato Y; Sato Y; Sezai S; Ikeda Y; Shinmura W; Watahiki H; Yamamoto H; Hioki Y; Suzuki M; Kumada T; Honda T; Rikitoku T; Hisanaga Y; Fukui H; Yamao J; Kawasaki H; Hosoda A; Onji M; Matsui H; Sata M; Torimura T; Oho K; Maekawa R; Takagi Y; Shakado S; Nakayama M; Gondo K; Fukushima H; Kusaba T; Tsubouchi H; Hayashi K; Hori T; Iida Y; Yutoku K; Maetani N; Kubo Y; Miyata Y
    Curr Ther Res Clin Exp; 2006 Jan; 67(1):1-20. PubMed ID: 24678081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].
    de Freitas JA; Lima LM; Ranieri JL; Olivieri JC; Fragoso HJ; Chinzon D
    Arq Gastroenterol; 2002; 39(1):60-5. PubMed ID: 12184168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.
    Sanuki T; Fujita T; Kutsumi H; Hayakumo T; Yoshida S; Inokuchi H; Murakami M; Matsubara Y; Kuwayama H; Kawai T; Miyaji H; Fujisawa T; Terao S; Yamazaki Y; Azuma T;
    J Gastroenterol; 2012 Nov; 47(11):1186-97. PubMed ID: 22526273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML; Enas N; Humphries TJ; Bassion S
    Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
    Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.
    Ji S; Kim HS; Kim JW; Jee MK; Park KW; Uh Y; Lee DK; Song JS; Baik SK; Kwon SO
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1381-7. PubMed ID: 16911680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
    Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Adachi K; Hashimoto T; Hamamoto N; Hirakawa K; Niigaki M; Miyake T; Taniura H; Ono M; Kaji T; Suetsugu H; Yagi J; Komazawa Y; Mihara T; Katsube T; Fujishiro H; Shizuku T; Hattori S; Yamamoto S; Kinoshita Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1392-8. PubMed ID: 14675268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.
    Shu X; Zhu Z; Fu Y; Zhang Z; Wang J; Li X; He S; Fan H; Liu S; Zhang G; Tang J; Huang C; Du Q; Wang X; Xu B; Du Y; Chen Q; Wang B; Chen Y; Duan X; Xie Y; Huo L; Hou X; Lu N
    Front Med (Lausanne); 2021; 8():690995. PubMed ID: 34336894
    [No Abstract]   [Full Text] [Related]  

  • 13. [A randomized, prospective, comparative, multicenter study of rabeprazole and ranitidine in the treatment of reflux esophagitis].
    Jeong HY; Lee BS; Sung JK; Lee TY; Yoon SJ; Kim SJ; Chung IK; Lee SH; Shin JE; Lee DS; Baek JT; Nam SW; Yoon SJ; Kim SH; Lee GS; Lee JM; Kim AN; Oh JI
    Korean J Gastroenterol; 2006 Jan; 47(1):15-21. PubMed ID: 16434864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer.
    Lay CS; Lin CJ
    J Chin Med Assoc; 2010 Apr; 73(4):188-93. PubMed ID: 20457439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
    Laheij RJ; Van Rossum LG; Jansen JB; Verheugt FW
    Aliment Pharmacol Ther; 2003 Jul; 18(1):109-15. PubMed ID: 12848632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
    Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
    J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Feb; 13(2):179-86. PubMed ID: 10102948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease.
    Pai V; Pai N
    World J Gastroenterol; 2007 Aug; 13(30):4100-2. PubMed ID: 17696229
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.